ACR.AX Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: October 24, 2024
Report Source: 2024 Annual Report
Acrux Ltd. Stock Analysis ACR.AX
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The firm is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Read More Acrux Ltd (ACR.AX) Chart
Key Statistics of Acrux Ltd (ACR.AX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
AUD0.01Volume
131.13KP/E Ratio (TTM)
-52 Week Range
Market Cap
4.52MAvg. Volume
154.45KDividend Yield
-Financial Metrics & Statements of Acrux Ltd (ACR.AX)
FAQ's for Acrux Ltd (ACR.AX)
- According to Musaffa’s Shariah screening methodology, Acrux Ltd (ACR.AX) is currently classified as HALAL as of October 2024. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.